Diabetes Drug Pioglitazone Linked to Bladder Cancer
Recent data suggests that use of Pioglitazone for over 2 years may increase a patient’s risk of developing bladder cancer. The drug, created to improve glycemic control in adults with type 2 diabetes mellitus by reducing insulin resistance, is currently under a safety review with the FDA. The review is based on a 10-year observational study of the long-term risk of bladder cancer in approximately 193,000 patients with diabetes who are members of the Kaiser Permanente Northern California health plan. Preliminary data analysis has shown an increasing risk of developing bladder cancer due to Pioglitazone exposure, a risk which reached statistical significance after only 24 months. Until final data from the FDA’s investigation is available, prescribing physicians should pay careful attention to this possible risk.
Fill out our contact form below for your free, no obligation case review.
Contact Our Orlando Attorney
If you have been injured in an accident, turn to Frank M. Eidson P.A. Whether your case is a simple collision or a complicated auto wrongful death case, contact personal injury lawyer Frank Eidson today to schedule your free consultation.